Dantari

Dantari is a biotechnology company that focuses on developing treatments for cancers along with other diseases. The company has developed an antibody-drug conjugate (ADC) platform with its Targeted High-capacity Drug Conjugate (T-HDC) technology, which enables a higher drug-to antibody ratio and larger payloads in drug development compared to traditional methods. 

The company’s pipeline consists of several T-HDC programs, including 1) DAN-22, which originates from Caltech, and, as of July 2023, was in a Phase I/II trial for HER2-negative breast cancer, 2) DAN-311, which targets HER3 to treat breast cancer and was slated for human testing in 2023, and 3) DAN-405, which targets PSMA to treat prostate cancer and was in the preclinical stage. Dantari’s candidates are being developed to use a variety of delivery systems, with its trials being currently carried out.

Funding and Financials

In December 2022, the company raised USD 47 million in a Series A funding round led by Westlake Village BioPartners. The funds were allocated toward further development of the company’s differentiated ADC and chemotherapeutic platforms.